Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma

References

• Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–15. doi: 10.1016/bs.acr.2020.10.001
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2021;19(12):2597–605 e4. doi: 10.1016/j.cgh.2020.08.065
   PubMed Web of Science ®Google Scholar
• Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards Screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603. doi: 10.1007/s12253-019-00585-5
   PubMed Web of Science ®Google Scholar
• Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456(7221):470–476. doi: 10.1038/nature07509
   PubMed Web of Science ®Google Scholar
• Bernard A, Hibos C, Richard C, et al. The tumor microenvironment impairs Th1 IFNgamma secretion through alternative splicing modifications of Irf1 pre-mRNA. Cancer Immunol Res. 2021;9(3):324–336. doi: 10.1158/2326-6066.CIR-19-0679
   PubMed Web of Science ®Google Scholar
• Kashyap A, Tripathi G, Tripathi A, et al. RNA splicing: a dual-edged sword for hepatocellular carcinoma. Med Oncol. 2022;39(11):173. doi: 10.1007/s12032-022-01726-8
   PubMed Web of Science ®Google Scholar
• Tremblay MP, Armero VE, Allaire A, et al. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma. BMC Genomics. 2016;17(1):683. doi: 10.1186/s12864-016-3029-z
   PubMedGoogle Scholar
• Yuan JH, Liu XN, Wang TT, et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol. 2017;19(7):820–832. doi: 10.1038/ncb3538
   PubMed Web of Science ®Google Scholar
• Martinez-Montiel N, Rosas-Murrieta NH, Anaya Ruiz M, et al. Alternative splicing as a target for cancer treatment. Int J Mol Sci. 2018;19(2). doi: 10.3390/ijms19020545
   PubMed Web of Science ®Google Scholar
• Yu S, Cai L, Liu C, et al. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma. Mol Med. 2021;27(1):36. doi: 10.1186/s10020-021-00294-3
   PubMed Web of Science ®Google Scholar
• Wang S, Wang S, Zhang X, et al. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer. RNA Biol. 2022;19(1):1007–1018. doi: 10.1080/15476286.2022.2113148
   PubMed Web of Science ®Google Scholar
• Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2014;33(46):5311–5318. doi: 10.1038/onc.2013.533
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi: 10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• D’Souza S, Lau KC, Coffin CS, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–5783. doi: 10.3748/wjg.v26.i38.5759
   PubMed Web of Science ®Google Scholar
• Silva AL, Faria M, Matos P. Inflammatory microenvironment modulation of alternative splicing in cancer: a way to adapt. Adv Exp Med Biol. 2020;1219:243–258. doi: 10.1007/978-3-030-34025-4_13
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu W, Zhang HM, et al. hTftarget: a Comprehensive database for regulations of human transcription factors and their targets. Int J Genomics Proteomics. 2020;18(2):120–128. doi: 10.1016/j.gpb.2019.09.006
   Google Scholar
• Dhanwani R, Takahashi M, Sharma S. Cytosolic sensing of immuno-stimulatory DNA, the enemy within. Curr Opin Immunol. 2018;50:82–87. doi: 10.1016/j.coi.2017.11.004
   PubMed Web of Science ®Google Scholar
• Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646. doi: 10.1016/j.ygeno.2020.02.015
   PubMed Web of Science ®Google Scholar
• Li Y, Qi D, Zhu B, et al. Analysis of m6A RNA methylation-related genes in liver hepatocellular carcinoma and their correlation with survival. Int J Mol Sci. 2021;22(3). doi: 10.3390/ijms22031474
   Web of Science ®Google Scholar
• Lee SE, Alcedo KP, Kim HJ, et al. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10(4):699–712. doi: 10.1016/j.jcmgh.2020.04.018
   PubMed Web of Science ®Google Scholar
• Huang S, Luo K, Jiang L, et al. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma. Sci Rep. 2021;11(1):23356. doi: 10.1038/s41598-021-02642-z
   PubMed Web of Science ®Google Scholar
• Yu L, Kim J, Jiang L, et al. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat Commun. 2020;11(1):708. doi: 10.1038/s41467-020-14437-3
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang H, Yu J, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20(1):6. doi: 10.1186/s12943-020-01299-y
   PubMed Web of Science ®Google Scholar
• Leier A, Moore M, Liu H, et al. Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I. Mol Ther Nucleic Acids. 2022;28:261–278. doi: 10.1016/j.omtn.2022.03.011
   PubMedGoogle Scholar
• Nabi AA, Atta SA, El-Ahwany E, et al. Taurine upregulates miRNA-122-5p expression and suppresses the metabolizing enzymes of glycolytic pathway in hepatocellular carcinoma. Mol Biol Rep. 2021;48(7):5549–5559. doi: 10.1007/s11033-021-06571-y
   PubMed Web of Science ®Google Scholar
• Afifi AM, El-Husseiny AM, Tabashy RH, et al. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects. Asian Pac J Cancer Prev. 2019;20(10):3007–3013. doi: 10.31557/APJCP.2019.20.10.3007
   PubMedGoogle Scholar
• Resh MD. Palmitoylation of proteins in cancer. Biochem Soc Trans. 2017;45(2):409–416. doi: 10.1042/BST20160233
   PubMed Web of Science ®Google Scholar
• Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896:173921. doi: 10.1016/j.ejphar.2021.173921
   PubMed Web of Science ®Google Scholar
• Liu S, Cai X, Wu J, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347(6227):aaa2630. doi: 10.1126/science.aaa2630
   PubMed Web of Science ®Google Scholar
• Zhao B, Shu C, Gao X, et al. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc Natl Acad Sci U S A. 2016;113(24):E3403–12. doi: 10.1073/pnas.1603269113
   PubMed Web of Science ®Google Scholar
• Petro TM. IFN regulatory factor 3 in health and disease. J Immunol. 2020;205(8):1981–1989. doi: 10.4049/jimmunol.2000462
   PubMed Web of Science ®Google Scholar
• Andrilenas KK, Ramlall V, Kurland J, et al. DNA-binding landscape of IRF3, IRF5 and IRF7 dimers: implications for dimer-specific gene regulation. Nucleic Acids Res. 2018;46(5):2509–2520. doi: 10.1093/nar/gky002
   PubMed Web of Science ®Google Scholar
• Shi HX, Yang K, Liu X, et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol. 2010;30(10):2424–2436. doi: 10.1128/MCB.01466-09
   PubMed Web of Science ®Google Scholar
• Karpova AY, Ronco LV, Howley PM. Functional characterization of interferon regulatory factor 3a (IRF-3a), an alternative splice isoform of IRF-3. Mol Cell Biol. 2001;21(13):4169–4176. doi: 10.1128/MCB.21.13.4169-4176.2001
   PubMed Web of Science ®Google Scholar
• Li Y, Hu X, Song Y, et al. Identification of novel alternative splicing variants of interferon regulatory factor 3. Biochim Biophys Acta. 2011;1809(3):166–175. doi: 10.1016/j.bbagrm.2011.01.006
   PubMed Web of Science ®Google Scholar
• Jiaze Y, Sinan H, Minjie Y, et al. Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments. Cancer Cell Int. 2022;22(1):114. doi: 10.1186/s12935-022-02533-x
   PubMed Web of Science ®Google Scholar
• Shin H, Cha HJ, Lee MJ, et al. Identification of ALDH6A1 as a Potential Molecular Signature in Hepatocellular Carcinoma via Quantitative Profiling of the Mitochondrial Proteome. J Proteome Res. 2020;19(4):1684–1695. doi: 10.1021/acs.jproteome.9b00846
   PubMed Web of Science ®Google Scholar
• Zhang T, Ma Z, Liu L, et al. DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway. Cell Death Dis. 2018;9(6):675. doi: 10.1038/s41419-018-0591-0
   PubMedGoogle Scholar
• Ouyang X, Lv L, Zhao Y, et al. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Front Oncol. 2021;11:801506. doi: 10.3389/fonc.2021.801506
   PubMed Web of Science ®Google Scholar
• Xing C, Xie H, Zhou L, et al. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation. Biochem Biophys Res Commun. 2012;420(1):29–35. doi: 10.1016/j.bbrc.2012.02.107
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu Z, Zhang S, et al. ShRNA-targeted centromere protein a inhibits hepatocellular carcinoma growth. PLoS One. 2011;6(3):e17794. doi: 10.1371/journal.pone.0017794
   PubMed Web of Science ®Google Scholar
• Gandhi M, Gross M, Holler JM, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020;11(1):3214. doi: 10.1038/s41467-020-17007-9
   PubMed Web of Science ®Google Scholar
• Yue H, Wu K, Liu K, et al. LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway. Cell Oncol. 2022;45(3):447–462. doi: 10.1007/s13402-022-00676-7
   Web of Science ®Google Scholar
• Huang DH, Jian J, Li S, et al. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol Med. 2019;44(6):2113–2122. doi: 10.3892/ijmm.2019.4371
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu L, Su T, et al. Autocrine STIP1 signaling promotes tumor growth and is associated with disease outcome in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017;493(1):365–372. doi: 10.1016/j.bbrc.2017.09.016
   PubMed Web of Science ®Google Scholar
• Mondal P, Sen S, Klein BJ, et al. TCF19 promotes cell proliferation through binding to the histone H3K4me3 mark. Biochemistry. 2020;59(4):389–399. doi: 10.1021/acs.biochem.9b00771
   PubMed Web of Science ®Google Scholar
• Mondal P, Gadad SS, Adhikari S, et al. TCF19 and p53 regulate transcription of TIGAR and SCO2 in HCC for mitochondrial energy metabolism and stress adaptation. FASEB J. 2021;35(9):e21814. doi: 10.1096/fj.202002486RR
   PubMed Web of Science ®Google Scholar
• Dong Y, Sun X, Zhang K, et al. Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating snail expression. Bioengineered. 2021;12(2):12967–12979. doi: 10.1080/21655979.2021.2012069
   PubMed Web of Science ®Google Scholar
• Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25(3):349–360. doi: 10.1016/j.immuni.2006.08.009
   PubMed Web of Science ®Google Scholar
• Ashley CL, Abendroth A, McSharry BP, et al. Interferon-independent innate responses to cytomegalovirus. Front Immunol. 2019;10:2751. doi: 10.3389/fimmu.2019.02751
   PubMed Web of Science ®Google Scholar